Cerebrolysin
Neuropeptide Preparation
Cerebrolysin is a peptide preparation derived from porcine brain tissue, studied in research for neurotrophic and neuroprotective signaling.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
Cerebrolysin is a peptide preparation derived from porcine brain tissue, studied in research for neurotrophic and neuroprotective signaling.
Experimental models examine its influence on neuronal survival and recovery pathways in neurological research frameworks.
Third-party tested for purity, ID, quantity.
Cerebrolysin is a standardized mixture of low-molecular-weight neuropeptides and amino acids characterized in research for neurotrophic activity resembling endogenous growth factors. Investigations have examined its effects on neuronal survival, plasticity, and recovery in stroke, traumatic-brain-injury, and neurodegeneration models.
Studies evaluate neuroprotective and neurorestorative endpoints under structured conditions.
Cerebrolysin was developed from research into brain-derived peptide preparations with neurotrophic activity.
A substantial body of clinical and preclinical literature has since examined its role in neurological recovery models.
Research into cerebrolysin focuses on neurotrophic and neuroprotective signaling. Frameworks evaluate neuronal survival, plasticity, and recovery endpoints across stroke, TBI, and neurodegeneration models under controlled conditions.
2 of the 4 areas below are addressed directly by a paper cited on this page.
Neurotrophic-factor signaling models
No paper cited on this page reports on neurotrophic or factor. This heading marks where Cerebrolysin is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Neuroprotection and recovery research
Addressed on this page by Brainin 2018. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Brainin, M. (2018) — Cerebrolysin: a multi-target drug for recovery after stroke
Stroke and TBI research frameworks
Addressed on this page by Brainin 2018. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Brainin, M. (2018) — Cerebrolysin: a multi-target drug for recovery after stroke
Neurodegeneration endpoint studies
No paper cited on this page reports on neurodegeneration or endpoint. This heading marks where Cerebrolysin is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 3 primary papers published between 2011 and 2023 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Cerebrolysin is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Cerebrolysin, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Cerebrolysin is also referred to as cere.
Cerebrolysin is commonly described online in connection with sharper focus, better memory and improved mood. In the research literature the same compound is filed under neurotrophic-factor signaling models, neuroprotection and recovery research and stroke and TBI research frameworks.
Of the 3 papers cited on this page, published between 2011 and 2023, 1 reports work in human participants — Jarosz 2023. Human data for a molecule is not the same as evidence for material supplied as a research compound: published trials use pharmaceutical-grade product under medical supervision at defined doses. What is established for the material sold here is its measured purity and content per lot.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Every lot of Cerebrolysin is independently assayed before it is released, and the certificate for the lot shipped is published rather than summarised. Where a certificate for a current lot is not yet posted, the lot has not yet been released against it.
Researchers who buy Cerebrolysin in the United States through Eppix Labs receive a batch-labelled vial whose certificate is published against that lot code, so the material can be matched to its analysis rather than to a generic specification.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Solvent selection depends on the compound; consult the published literature
- Format
- Lyophilized powder
Cerebrolysin is supplied as lyophilized powder. It is not a peptide, and solvent behaviour follows from its own chemistry rather than from the aqueous-vehicle conventions that apply to peptide material — the published literature for this compound is the reference for solvent selection, not a general peptide protocol.
Dry storage below freezing and protection from light are the general controls. As with any lyophilized material, the powder frequently sits as a thin film at the base of the vial and is easy to mistake for an empty vial before inspection.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
- 1 × sealed glass vial in the strength selected (30mg / Single Vial, 60mg / Single Vial, 30mg / 5-Pack, 30mg / 10-Pack, 60mg / 5-Pack, 60mg / 10-Pack available), batch-labelled
- Batch documentation for the lot shipped, once its certificate is published
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of cerebrolysin. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Related
You May Also Like
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
From$79.99
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
From$39.99
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
From$59.99
Long-acting amylin analog engineered for appetite signaling, metabolic control, and energy balance research
From$99.99